Page last updated: 2024-11-06

fluoren-9-ol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Fluoren-9-ol is a white solid compound that is a key intermediate in the synthesis of various pharmaceutical agents. Its structure comprises a fluorene core with a hydroxyl group at the 9-position. Fluoren-9-ol has been extensively studied due to its potential applications in various fields, including organic synthesis, pharmaceuticals, and materials science. It is synthesized by reacting fluorene with an oxidizing agent such as potassium permanganate. Fluoren-9-ol exhibits interesting properties such as its ability to act as a chiral catalyst and its use as a building block for various organic compounds. It has also been found to possess antibacterial activity against certain bacterial strains. The compound's importance lies in its versatility as a synthetic intermediate and its potential applications in various fields, prompting researchers to investigate its properties and applications further.'
```

fluoren-9-ol : A member of the class of hydroxyfluorenes that is 9H-fluorene substituted by a hydroxy group at position 9 (the non-aromatic carbon). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID96087
SCHEMBL ID58474
MeSH IDM0126166
PubMed CID74318
CHEMBL ID571548
CHEBI ID16904
SCHEMBL ID216862
MeSH IDM0126166

Synonyms (61)

Synonym
HMS1577P21
fluoren-1-ol
nsc51310
6344-61-2
nsc-51310
9h-fluoren-1-ol
AKOS006283802
9h-fluorenol
28724-53-0
nsc 51310
FT-0636110
SCHEMBL58474
PWFLISNWYDWJHX-UHFFFAOYSA-N
cambridge id 5135308
1-fluorenol
DTXSID40951380
BIDD:ER0390
AC-4876
9h-fluoren-9-ol
fluorenol
nsc-5320
nsc5320
CHEBI:16904 ,
9-fluorenol
1689-64-1
diphenylene carbinol
9-hydroxyfluorene
C06711
fluoren-9-ol
inchi=1/c13h10o/c14-13-11-7-3-1-5-9(11)10-6-2-4-8-12(10)13/h1-8,13-14h
afmveszoykhdbj-uhfffaoysa-
9-hydroxyfluorene, 96%
BMSE000564
zinc00968252
9-hydroxy fluorene
CHEMBL571548 ,
F0229
bdbm50303916
AKOS000120836
A811041
bv0q72r613 ,
unii-bv0q72r613
einecs 216-879-0
nsc 5320
FT-0621649
SCHEMBL216862
9-fluorenyl alcohol
9-hydroxy-9h-fluorene
DTXSID4052683
Q-101164
9h-fluorene-9-ol
mfcd00001135
DS-5094
CS-W017104
Q5462806
alpha-dansyl-l-argininehydrochloride
F14877
EN300-20827
SY049604
HY-W016388
Z104483208
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
animal metaboliteAny eukaryotic metabolite produced during a metabolic reaction in animals that include diverse creatures from sponges, insects to mammals.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
hydroxyfluorenesAny member of the class of fluorenes containing a mono- or poly-substituted fluorene ring in which at least one of the substituents is a hydroxy group.
secondary alcoholA secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
fluorene degradation II09
fluorene degradation I015

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Indoleamine 2,3-dioxygenase 1Homo sapiens (human)IC50 (µMol)1,000.00000.05373.075710.0000AID443993
Sodium-dependent dopamine transporterRattus norvegicus (Norway rat)IC50 (µMol)9.00000.00070.97749.7000AID661805
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (19)

Processvia Protein(s)Taxonomy
regulation of activated T cell proliferationIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of T cell tolerance inductionIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of chronic inflammatory responseIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of type 2 immune responseIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
tryptophan catabolic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
inflammatory responseIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
female pregnancyIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
tryptophan catabolic process to kynurenineIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
response to lipopolysaccharideIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
negative regulation of interleukin-10 productionIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of interleukin-12 productionIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
multicellular organismal response to stressIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
kynurenic acid biosynthetic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
swimming behaviorIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
T cell proliferationIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
negative regulation of T cell proliferationIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
negative regulation of T cell apoptotic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of T cell apoptotic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
'de novo' NAD biosynthetic process from tryptophanIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
electron transfer activityIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
heme bindingIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
indoleamine 2,3-dioxygenase activityIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
metal ion bindingIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
tryptophan 2,3-dioxygenase activityIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
cytosolIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
smooth muscle contractile fiberIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
stereocilium bundleIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
cytoplasmIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159537qHTS screening for TAG (triacylglycerol) accumulators in algae2017Plant physiology, Aug, Volume: 174, Issue:4
Identification and Metabolite Profiling of Chemical Activators of Lipid Accumulation in Green Algae.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID661888AUC (0 to t) in rat plasma assessed as 9H-fluoren-9-ol at 116 mg/kg, ip2012Bioorganic & medicinal chemistry letters, Jun-01, Volume: 22, Issue:11
Wake promoting agents: search for next generation modafinil, lessons learned: part III.
AID661813Wake promoting activity in dog2012Bioorganic & medicinal chemistry letters, Jun-01, Volume: 22, Issue:11
Wake promoting agents: search for next generation modafinil, lessons learned: part III.
AID661805Displacement of 3H-WIN-35428 from DAT in rat striata after 120 mins2012Bioorganic & medicinal chemistry letters, Jun-01, Volume: 22, Issue:11
Wake promoting agents: search for next generation modafinil, lessons learned: part III.
AID661886Cmax in rat plasma assessed as 9H-fluoren-9-ol at 116 mg/kg, ip2012Bioorganic & medicinal chemistry letters, Jun-01, Volume: 22, Issue:11
Wake promoting agents: search for next generation modafinil, lessons learned: part III.
AID661887Tmax in rat plasma assessed as 9H-fluoren-9-ol at 116 mg/kg, ip2012Bioorganic & medicinal chemistry letters, Jun-01, Volume: 22, Issue:11
Wake promoting agents: search for next generation modafinil, lessons learned: part III.
AID661890Tmax in rat brain assessed as 9H-fluoren-9-ol at 116 mg/kg, ip2012Bioorganic & medicinal chemistry letters, Jun-01, Volume: 22, Issue:11
Wake promoting agents: search for next generation modafinil, lessons learned: part III.
AID661889Cmax in rat brain assessed as 9H-fluoren-9-ol at 116 mg/kg, ip2012Bioorganic & medicinal chemistry letters, Jun-01, Volume: 22, Issue:11
Wake promoting agents: search for next generation modafinil, lessons learned: part III.
AID661806Wake promoting activity in rat assessed as total time awake at 100 mg/kg, ip over a period of 3 hrs after dosing2012Bioorganic & medicinal chemistry letters, Jun-01, Volume: 22, Issue:11
Wake promoting agents: search for next generation modafinil, lessons learned: part III.
AID661891AUC (0 to t) in rat brain assessed as 9H-fluoren-9-ol at 116 mg/kg, ip2012Bioorganic & medicinal chemistry letters, Jun-01, Volume: 22, Issue:11
Wake promoting agents: search for next generation modafinil, lessons learned: part III.
AID443993Inhibition of human recombinant IDO expressed in Escherichia coli BL21 AI2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Rational design of indoleamine 2,3-dioxygenase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (13.33)29.6817
2010's9 (60.00)24.3611
2020's4 (26.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.47

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.47 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.77 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.47)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]